<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of the sample.</title><p>The values presented in the table correspond to means followed by (standard deviations). MMSE, mini-mental state examination. Amyloid positivity (Amyloid<bold>-</bold>&#946;+) was established using a composite cortical region normalized by the whole cerebellum on <sup>18</sup>F-Flutemetamol PET with a cut-off of&#160;&gt;0.693. Subjects with values below this cut-off were classified as amyloid negative (Amyloid-&#946;&#8722;). P values were calculated using Chi-square tests (to assess differences in sex) or Mann-Whitney tests (to assess differences in all other variables).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th colspan="2" valign="top">Cognitively normal <break/>(CN)</th><th valign="top">Mild cognitive impairment <break/>(MCI)</th><th valign="top">Alzheimer&#8217;s disease <break/>(AD)</th></tr><tr><th valign="top"/><th valign="top">amyloid-&#946; &#8722; <break/>(n&#160;=&#160;26)</th><th valign="top">amyloid-&#946;+ <break/>(n&#160;=&#160;34)</th><th valign="top">All amyloid-&#946;+ <break/>(n&#160;=&#160;21)</th><th valign="top">All amyloid-&#946;+ <break/>(n&#160;=&#160;36)</th></tr></thead><tbody><tr><td valign="top">Age (years)</td><td valign="top">74.9 (5.7)</td><td valign="top">75.2 (6.1)</td><td valign="top">72.3 (6.9)</td><td valign="top">70.6 (8.2)<sup>b, d</sup></td></tr><tr><td valign="top">Sex (m/f)</td><td valign="top">15/11</td><td valign="top">14/20</td><td valign="top">14/7</td><td valign="top">20/16</td></tr><tr><td valign="top">Education (years)</td><td valign="top">12.2 (3.5)</td><td valign="top">11.7 (3.7)</td><td valign="top">12.1 (3.5)</td><td valign="top">12.2 (3.4)</td></tr><tr><td valign="top">MMSE</td><td valign="top">28.8 (1.1)</td><td valign="top">29.1 (1.1)</td><td valign="top">26.0 (2.7)<sup>a, c</sup></td><td valign="top">20.6 (5.3)<sup>b, d, e</sup></td></tr><tr><td valign="top">Delayed recall</td><td valign="top">2.2 (1.7)</td><td valign="top">2.6 (2.2)</td><td valign="top">5.9 (2.4) <sup>a,c</sup></td><td valign="top">8.3 (2.0)<sup>b, d, e</sup></td></tr><tr><td valign="top">Trail making test A</td><td valign="top">44.4 (15.4)</td><td valign="top">51.6 (19.5)</td><td valign="top">59.4 (18.9)<sup>a</sup></td><td valign="top">83.4 (54.1)<sup>b, d</sup></td></tr><tr><td valign="top">Clock-drawing test</td><td valign="top">2.71 (1.19)</td><td valign="top">2.80 (1.52)</td><td valign="top">5.09 (1.08)<sup>a, c</sup></td><td valign="top">6.18 (1.58)<sup>b, d</sup></td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Significant differences between amyloid negative controls and mild cognitive impairment patients (p&lt;0.05).</p><p><sup>b</sup> Significant differences between amyloid negative controls and Alzheimer&#8217;s disease dementia patients (p&lt;0.05).</p></fn><fn><p><sup>c</sup> Significant differences between amyloid positive controls and mild cognitive impairment patients (p&lt;0.05).</p><p><sup>d</sup> Significant differences between amyloid positive controls and Alzheimer&#8217;s disease dementia patients (p&lt;0.05).</p></fn><fn><p><sup>e</sup> Significant differences between mild cognitive impairment and Alzheimer&#8217;s disease dementia patients (p&lt;0.05).</p></fn></table-wrap-foot></table-wrap>